CN101946769A - Application of sulfanilamide in preparing anti-tobacco-mosaic-virus medicine - Google Patents
Application of sulfanilamide in preparing anti-tobacco-mosaic-virus medicine Download PDFInfo
- Publication number
- CN101946769A CN101946769A CN2010102910573A CN201010291057A CN101946769A CN 101946769 A CN101946769 A CN 101946769A CN 2010102910573 A CN2010102910573 A CN 2010102910573A CN 201010291057 A CN201010291057 A CN 201010291057A CN 101946769 A CN101946769 A CN 101946769A
- Authority
- CN
- China
- Prior art keywords
- sulfanilamide
- virus
- tmv
- application
- tobacco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides an application of sulfanilamide in preparing an anti-tobacco-mosaic-virus medicine. Proven by test results, the sulfanilamide can noticeably inhibit initial infestation of TMV to the host, reduce chances that the virus enters host cells, duplicates and proliferates and plays the role of protecting the host; in addition, the sulfanilamide features better inhibition ratio of TMV infestation than the inhibition ratio of TMV infestation of the anti-virus pesticide 'virus killer'.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, particularly, relate to the application of sulfanilamide (SN) as the preparation of prevention and control tobacco mosaic.
Background technology:
Tobacco mosaic virus disease is one of main disease of cured tobacco production.(Sulfonamides SAs) is meant the general name of the class medicine with P-aminobenzene-sulfonamide structure to sulfa drugs, is the chemotherapeutic agent that a class is used to prevent and treat bacterial infection disease.If hinder the bacterium nucleic acid, the synthetic generation obstacle of nucleic acid has also just influenced the formation of nucleoprotein, so bacterium can not growth and breeding.The sulfa drugs kind of synthetic is a lot of now, but also is bringing in constant renewal in.Commonly used has: sulphathiazole, sulphadiazine, SMZco etc. all can be used to treat epidemic meningitis.
Summary of the invention
The purpose of this invention is to provide the application of sulfanilamide (SN) in preparation resisting tobacco mosaic virus medicine.
For achieving the above object, the invention provides following technical scheme:
The application of sulfanilamide (SN) shown in the following structural formula in preparation resisting tobacco mosaic virus medicine,
When The compounds of this invention is used as medicine, can directly use, perhaps use with the form of pharmaceutical composition.This pharmaceutical composition contains 0.1-99%, is preferably the The compounds of this invention of 0.5-90%, and all the other are acceptable on the pharmacology, the pharmaceutically suitable carrier and/or the excipient of and inertia nontoxic to humans and animals.Described pharmaceutical carrier or excipient are one or more solids, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.The method that adopts pharmacy and field of food to generally acknowledge is prepared into various formulations, as liquid preparation (injection, supensoid agent, emulsion, solution, syrup etc.), solid pharmaceutical preparation (tablet, capsule, granule, electuary etc.), spray, aerosol etc.
Description of drawings:
The inhibition effect that Fig. 1 infects TMV on Nicotiana glutinosa for sulfanilamide (SN) of the present invention (wherein left half leaf is for only inoculating TMV, and right half leaf is a compound treatment).
Embodiment:
Below in conjunction with accompanying drawing, further specify essentiality content of the present invention with concrete instance of the present invention, but content of the present invention is not limited thereto.
Embodiment 1:
The withered spot method of Nicotiana glutinosa half leaf: select healthy suitable Nicotiana glutinosa, a night is placed in the darkroom.Every cigarette is selected 3 identical blades of horizontal level.With concentration be the TMV of 0.032 μ g/ μ l and the compound sulfanilamide (SN) solution of 50 μ g/ml (experiment with compound in 2006 available from Nat'l Pharmaceutical ﹠ Biological Products Control Institute, be the drug inspection reference substance.The mother liquor that compound is dissolved into 10mg/ml with the inferior maple of dimethyl (DMSO) is in 4 ℃ of preservations, faces the time spent to be diluted to desired concn with sterile water.The final concentration 25 μ l/ml of DMSO do not have influence to experimental result.) mix 15min after frictional inoculation in Nicotiana glutinosa blade right half part 100 μ l, the TMV100 μ l of blade left-half frictional inoculation equal concentrations is positive control, and is clean with aseptic water washing behind the 10min.To test the cigarette seedling puts into no worm net cage and cultivates, the withered spot number order of half leaf about 72h statistics blade, and computerized compound sulfanilamide (SN) inhibiting rate=[(positive control withered spot number-compound treatment withered spot number)/positive control withered spot number] * 100% that TMV is infected by formula.
Because Nicotiana glutinosa belongs to the withered spot host of TMV, can judge whether compound has suppressed first the infecting of virus by the blade of a comparison virus inoculation with through the withered spot number amount and the withered spot size of compound treatment blade.The inhibition effect that Fig. 1 infects TMV on the Nicotiana glutinosa when 50 μ g/ml for compound sulfanilamide (SN), wherein left half leaf is for only inoculating TMV, and right half leaf is inoculated processing for virus after compound treatment.By part withered spot number order contrast about blade as can be known, compound sulfanilamide (SN) can significantly suppress TMV the first of host infected, thereby minimizing virus enters host cell and further duplicates and value-added chance, plays the effect to host's protection.Table 1 for compound sulfanilamide (SN) when 50 μ g/ml and control drug " virus must the restrain " comparison of on Nicotiana glutinosa, TMV being infected inhibiting rate, by the result as can be known, the inhibiting rate that compound sulfanilamide (SN) infects TMV is better than commercial anti viral pesticide " virus must restrain ".
Table 1 compound sulfanilamide (SN) must restrain the comparison of TMV being infected inhibiting rate on Nicotiana glutinosa with virus
Claims (1)
1. the application of sulfanilamide (SN) shown in the following structural formula in preparation resisting tobacco mosaic virus medicine,
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102910573A CN101946769A (en) | 2010-09-26 | 2010-09-26 | Application of sulfanilamide in preparing anti-tobacco-mosaic-virus medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102910573A CN101946769A (en) | 2010-09-26 | 2010-09-26 | Application of sulfanilamide in preparing anti-tobacco-mosaic-virus medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101946769A true CN101946769A (en) | 2011-01-19 |
Family
ID=43450495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102910573A Pending CN101946769A (en) | 2010-09-26 | 2010-09-26 | Application of sulfanilamide in preparing anti-tobacco-mosaic-virus medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101946769A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115322147A (en) * | 2022-08-26 | 2022-11-11 | 贵州理工学院 | Benzene sulfonamide derivative, preparation method and application |
-
2010
- 2010-09-26 CN CN2010102910573A patent/CN101946769A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| CAS: "STN-CAplus AN:1958:31845", 《STN COLUMBUS》 * |
| TERENCE M. MURPHY: "INACTIVATION OF TOBACCO MOSAIC VIRUS RIBONUCLEIC ACID BY NEAR- AND MIDDLE- ULTRAVIOLET LIGHT: SENSITIZATION BY SULFANILAMIDE AND CHLORTETRACYCLINE", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115322147A (en) * | 2022-08-26 | 2022-11-11 | 贵州理工学院 | Benzene sulfonamide derivative, preparation method and application |
| CN115322147B (en) * | 2022-08-26 | 2023-08-08 | 贵州理工学院 | Benzenesulfonamide derivative, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102151256B (en) | Application of protocatechuic acid in preparation of drugs for preventing and controlling livestock and poultry virus infectious diseases | |
| CN113082049B (en) | New application of potassium iodide or composition containing potassium iodide in preparation of drugs for treating African swine fever | |
| CN108721281A (en) | New antiviral drugs and its application | |
| CN103109812B (en) | Application of sesquiterpene lactone in trilobe wedelia in preparation of medicine for resisting tobacco mosaic virus (TMV) | |
| CN105010358A (en) | Bactericidal composition and application thereof | |
| CN101946771B (en) | Application of Saikosaponin A to preparing pesticide for resisting tobacco mosaic virus (TMV) | |
| CN109568301A (en) | A kind of gallic acid, Rhein compound prescription preparation method and applications | |
| CN106880630B (en) | Retro-2cyclAnd use of related derivatives | |
| CN101069714A (en) | Medicine for preventing and treating fowl's respiratory tract diseases and preparing method | |
| CN101946784B (en) | Application of ginkgolides B to preparation of tobacco mosaic virus resistant medicament | |
| CN104083433A (en) | External veterinary medicine composition for treating animal scabies, and application and preparation method thereof | |
| CN102283838B (en) | Application of ethoxysanguinarine to pharmacy | |
| CN101946769A (en) | Application of sulfanilamide in preparing anti-tobacco-mosaic-virus medicine | |
| CN114146071B (en) | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | |
| CN103655684A (en) | Traditional Chinese herbal medicine microecological preparation capable of killing and inhibiting foot and mouth disease virus in vitro and in vivo | |
| CN101946770B (en) | Application of 6-O-caffeoyl erigeroside in preparing tobacco mosaic virus resistant medicament | |
| CN102772398A (en) | Application of dihydromyricetin in preparation of drug preventing and treating influenza | |
| CN106957826B (en) | Virus inactivating agent and application thereof | |
| CN111317752A (en) | Medicine for preventing or treating influenza virus infection and application | |
| CN106822176B (en) | The purposes of lithium chloride inhibition foot and mouth disease virus | |
| EP1731159A1 (en) | Method of preventing nodavirus infection and therapeutic method | |
| CN115778952A (en) | Application of papaya alkaloid in preparation of anti-neocoronavirus medicines | |
| CN108272788B (en) | Puerarin is in the drug and pig feed additive for preparing the purposes in the drug for preventing and treating pig virus infection, preventing and treating pig virus infection | |
| CN108472311A (en) | The method of antivirotic and treatment virus infection | |
| CN105012293A (en) | Medicine for treating hemorrhagic fever with renal syndrome and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110119 |